featured
GP2015 Comparable With Etanercept Originator in Efficacy and Safety in Chronic Plaque-Type Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The British Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The EGALITY Study: A Confirmatory, Randomised, Double-Blind Study Comparing the Efficacy, Safety and Immunogenicity of GP2015, a Proposed Etanercept Biosimilar, Versus the Originator Product in Patients With Moderate to Severe Chronic Plaque-Type Psoriasis
Br J Dermatol 2016 Oct 27;[EPub Ahead of Print], CE Griffiths, D Thaçi, S Gerdes, P Arenberger, G Pulka, K Kingo, J Weglowska, , N Hattebuhr, J Poetzl, H Woehling, G Wuerth, M AfonsoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.